<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988674</url>
  </required_header>
  <id_info>
    <org_study_id>P15-672</org_study_id>
    <nct_id>NCT02988674</nct_id>
  </id_info>
  <brief_title>A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation</brief_title>
  <acronym>Adherence</acronym>
  <official_title>Prospective, Multi-Center, Observational, Program to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to access retention rate, persistence and adherence in
      population of spondylarthritis (SpA) (ankylosing spondylitis (AS) and psoriatic arthritis
      (PsA)) participants treated with adalimumab in routine clinical settings in the Russian
      Federation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2016</start_date>
  <completion_date type="Anticipated">November 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants on adalimumab therapy</measure>
    <time_frame>Up to 30 days after administering last dose in the study (52 weeks)</time_frame>
    <description>This is used to assess retention rate. Persistence/Adherence of SpA patient to treatment, as well as retention rate, is an important factor of achieving of treatment goals. Medical non-adherence poses a significant limitation to treating to target in RA and SpA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants on adalimumab therapy</measure>
    <time_frame>Up to 30 days after administering last dose in the study (52 weeks)</time_frame>
    <description>This is used to assess retention rate. Persistence/Adherence of SpA patient to treatment, as well as retention rate, is an important factor of achieving of treatment goals. Medical non-adherence poses a significant limitation to treating to target in rheumatoid arthritis (RA) and SpA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing medication persistence</measure>
    <time_frame>Up to 48 weeks of treatment period</time_frame>
    <description>Medication persistence is defined as the duration of time from initiation to discontinuation of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing medication adherence</measure>
    <time_frame>Up to 48 weeks of treatment period</time_frame>
    <description>Medication adherence is defined as the extent to which a participant acts in accordance with the prescribed interval and dose of a dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of disease activity in participants with PsA</measure>
    <time_frame>Up to 48 weeks of treatment period</time_frame>
    <description>This is assessed using Disease activity score 28 joints count (DAS28) in participants with PsA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of disease activity in participants with AS</measure>
    <time_frame>Up to 48 weeks of treatment period</time_frame>
    <description>This is assessed using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in participants with AS.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">139</enrollment>
  <condition>Spondylarthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Participants with Spondylarthritis</arm_group_label>
    <description>Participants with Spondylarthritis (ankylosing spondylitis and psoriatic arthritis) treated with adalimumab in routine clinical settings in the Russian Federation.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Spondylarthritis (ankylosing spondylitis and psoriatic arthritis) participants treated with
        adalimumab in routine clinical settings in the Russian Federation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of AS or PsA.

          -  Planned prescription or prescribed no more than 1 month before to enrolment therapy
             with adalimumab. Treatment has to be prescribed according to the local product label
             and prescription guidelines.

          -  At the moment of start of treatment with adalimumab moderate/severe AS or PsA (BASDAI
             &gt; 4 for AS; DAS28 &gt;3,2 for PsA).

          -  Negative result of tuberculosis (TB) screening test and TB specialist permission to
             start biologic therapy.

          -  Authorization (Consent) for Use/Disclosure of Data signed by the participant.

        Exclusion Criteria:

          -  Has contraindications for the treatment with adalimumab (please see the latest version
             of the locally approved label).

          -  Participants who are unable to walk and perform basic self-care activities either due
             to SpA or a comorbid condition.

          -  Any biologic drugs taken over before 3 months of enrollment to the study.

          -  Previous participation in this program.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilya Shibanov</last_name>
    <phone>+7 495 258 4270 Extn 56175</phone>
    <email>ilya.shibanov@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrey Potapov</last_name>
    <phone>+7-926-130-8820</phone>
    <email>andrey.potapov@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clin Hosp</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454092</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ivanovo Regional Clinical Hosp</name>
      <address>
        <city>Ivanovo</city>
        <zip>153040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kemerovo Regional Hospital</name>
      <address>
        <city>Kemerovo</city>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institution KhMAO-Ugra</name>
      <address>
        <city>Khanty-mansiysk</city>
        <zip>628011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Clinical policlinic</name>
      <address>
        <city>Moscow</city>
        <zip>107023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Research Institute</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Institute of Rheum</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advisory-diagnostic Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>117041</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #1 n.a.</name>
      <address>
        <city>Moscow</city>
        <zip>117049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diagnostic Center # 5 of Mosco</name>
      <address>
        <city>Moscow</city>
        <zip>127572</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GBUZ Republican Hospital</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smolensk station JSC Russian R</name>
      <address>
        <city>Smolensk</city>
        <zip>214025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nort-Western State Medical Uni</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tula Regional Clinical Hospita</name>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yaroslavi State Medical Univer</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2016</study_first_submitted>
  <study_first_submitted_qc>December 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adalimumab</keyword>
  <keyword>Ankylosing spondylitis</keyword>
  <keyword>Psoriatic arthritis</keyword>
  <keyword>Spondylarthritis</keyword>
  <keyword>Humira®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

